265 related articles for article (PubMed ID: 35022195)
1. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.
Reppel L; Tsahouridis O; Akulian J; Davis IJ; Lee H; Fucà G; Weiss J; Dotti G; Pecot CV; Savoldo B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022195
[TBL] [Abstract][Full Text] [Related]
2. GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.
Ciccone R; Quintarelli C; Camera A; Pezzella M; Caruso S; Manni S; Ottaviani A; Guercio M; Del Bufalo F; Quadraccia MC; Orlando D; Di Cecca S; Sinibaldi M; Aurigemma M; Iaffaldano L; Sarcinelli A; D'Amore ML; Ceccarelli M; Nazio F; Marabitti V; Giorda E; Pezzullo M; De Stefanis C; Carai A; Rossi S; Alaggio R; Del Baldo G; Becilli M; Mastronuzzi A; De Angelis B; Locatelli F
Clin Cancer Res; 2024 Jun; 30(11):2545-2557. PubMed ID: 38551501
[TBL] [Abstract][Full Text] [Related]
3. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.
Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T
Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720
[TBL] [Abstract][Full Text] [Related]
5. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
6. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
[TBL] [Abstract][Full Text] [Related]
7. GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.
Gargett T; Ebert LM; Truong NTH; Kollis PM; Sedivakova K; Yu W; Yeo ECF; Wittwer NL; Gliddon BL; Tea MN; Ormsby R; Poonnoose S; Nowicki J; Vittorio O; Ziegler DS; Pitson SM; Brown MP
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167468
[TBL] [Abstract][Full Text] [Related]
8. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
Andersch L; Radke J; Klaus A; Schwiebert S; Winkler A; Schumann E; Grunewald L; Zirngibl F; Flemmig C; Jensen MC; Rossig C; Joussen A; Henssen A; Eggert A; Schulte JH; Künkele A
BMC Cancer; 2019 Sep; 19(1):895. PubMed ID: 31500597
[TBL] [Abstract][Full Text] [Related]
9. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
10. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.
Seitz CM; Schroeder S; Knopf P; Krahl AC; Hau J; Schleicher S; Martella M; Quintanilla-Martinez L; Kneilling M; Pichler B; Lang P; Atar D; Schilbach K; Handgretinger R; Schlegel P
Oncoimmunology; 2020; 9(1):1683345. PubMed ID: 32002293
[TBL] [Abstract][Full Text] [Related]
11. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.
Tanaka M; Tashiro H; Omer B; Lapteva N; Ando J; Ngo M; Mehta B; Dotti G; Kinchington PR; Leen AM; Rossig C; Rooney CM
Clin Cancer Res; 2017 Jul; 23(14):3499-3509. PubMed ID: 28183713
[No Abstract] [Full Text] [Related]
12. EZH2 Inhibition in Ewing Sarcoma Upregulates G
Kailayangiri S; Altvater B; Lesch S; Balbach S; Göttlich C; Kühnemundt J; Mikesch JH; Schelhaas S; Jamitzky S; Meltzer J; Farwick N; Greune L; Fluegge M; Kerl K; Lode HN; Siebert N; Müller I; Walles H; Hartmann W; Rossig C
Mol Ther; 2019 May; 27(5):933-946. PubMed ID: 30879952
[TBL] [Abstract][Full Text] [Related]
13. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.
Singh N; Liu X; Hulitt J; Jiang S; June CH; Grupp SA; Barrett DM; Zhao Y
Cancer Immunol Res; 2014 Nov; 2(11):1059-70. PubMed ID: 25104548
[TBL] [Abstract][Full Text] [Related]
14. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
Front Immunol; 2020; 11():99. PubMed ID: 32117253
[TBL] [Abstract][Full Text] [Related]
15. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma.
Moghimi B; Muthugounder S; Jambon S; Tibbetts R; Hung L; Bassiri H; Hogarty MD; Barrett DM; Shimada H; Asgharzadeh S
Nat Commun; 2021 Jan; 12(1):511. PubMed ID: 33479234
[TBL] [Abstract][Full Text] [Related]
16. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
[TBL] [Abstract][Full Text] [Related]
17. Targeting CDH17 with Chimeric Antigen Receptor-Redirected T Cells in Small Cell Lung Cancer.
Tian W; Zhao J; Wang W
Lung; 2023 Oct; 201(5):489-497. PubMed ID: 37823901
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells.
Yvon E; Del Vecchio M; Savoldo B; Hoyos V; Dutour A; Anichini A; Dotti G; Brenner MK
Clin Cancer Res; 2009 Sep; 15(18):5852-60. PubMed ID: 19737958
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
20. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M
Mount CW; Majzner RG; Sundaresh S; Arnold EP; Kadapakkam M; Haile S; Labanieh L; Hulleman E; Woo PJ; Rietberg SP; Vogel H; Monje M; Mackall CL
Nat Med; 2018 May; 24(5):572-579. PubMed ID: 29662203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
